drugset / Trial / NCT05722405
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Phase 4
Recruiting
100 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Affiliated Hospital of Jiaxing University · collabDongyang People's Hospital · collabHuzhou Central Hospital · collabLishui Country People's Hospital · collabShangyu People's Hospital · collabShaoxing People's Hospital · collabShaoxing Second Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Ixazomib combined with low-dose lenalidomide(10mg) vs Ixazomib alone as maintenance regimen in patients with high-risk multiple myeloma after induction and consolidation of VRD-based regimen.
Timeline
- Start
- 2022-07-01
- Primary completion
- 2026-06-30
- Completion
- 2028-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixazomib | Unknown | — | Oral |
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |